Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Muckenhirn Keith E
2. Date of Event Requiring Statement (Month/Day/Year)
09/04/2016
3. Issuer Name and Ticker or Trading Symbol
ANTARES PHARMA, INC. [ATRS]
(Last)
(First)
(Middle)
C/O ANTARES PHARMA, INC., 100 PRINCETON SOUTH, SUITE 300
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
VP/Controller & Interim CFO
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

EWING, NJ 08628
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 50,000
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) 01/16/2010(1) 01/15/2017 Common Stock $0.01 par value per share 30,000 $ 1.23 D  
Stock Option (right to buy) 05/10/2010(1) 05/09/2017 Common Stock $0.01 par value per share 15,000 $ 1.65 D  
Stock Option (right to buy) 05/14/2011(1) 05/13/2018 Common Stock $0.01 par value per share 45,000 $ 0.85 D  
Stock Option (right to buy) 11/12/2011(1) 11/11/2018 Common Stock $0.01 par value per share 20,000 $ 0.47 D  
Stock Option (right to buy) 11/11/2012(1) 11/11/2019 Common Stock $0.01 par value per share 45,000 $ 1.1 D  
Stock Option (right to buy) 11/11/2013(1) 11/10/2020 Common Stock $0.01 par value per share 35,000 $ 1.52 D  
Stock Option (right to buy) 05/17/2015(1) 05/16/2022 Common Stock $0.01 par value per share 20,000 $ 2.94 D  
Stock Option (right to buy) 05/22/2016(1) 05/22/2023 Common Stock $0.01 par value per share 30,000 $ 3.96 D  
Stock Option (right to buy)   (2) 11/19/2024 Common Stock $0.01 par value per share 35,000 $ 2.29 D  
Stock Option (right to buy)   (3) 05/29/2024 Common Stock $0.01 par value per share 35,000 $ 3.09 D  
Stock Option (right to buy)   (4) 05/28/2025 Common Stock $0.01 par value per share 35,000 $ 2.18 D  
Stock Option (right to buy)   (5) 06/02/2026 Common Stock $0.01 par value per share 40,000 $ 1.12 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Muckenhirn Keith E
C/O ANTARES PHARMA, INC.
100 PRINCETON SOUTH, SUITE 300
EWING, NJ 08628
      VP/Controller & Interim CFO  

Signatures

Keith Muckenhirn 09/12/2016
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options vested in equal quarterly installments over three years from the initial grant date. The exercisable date listed above represents the date the options became fully vested and exercisable.
(2) Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted on November 20, 2014 and are vesting in equal quarterly installments over three years from the initial grant date.
(3) Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted on May 29, 2014 and are vesting in equal quarterly installments over three years from the initial grant date.
(4) Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted on May 28, 2015 and are vesting in equal quarterly installments over three years from the initial grant date.
(5) Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted on June 2, 2016 and are vesting in equal quarterly installments over three years from the initial grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.